Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen

Conditions:   HIV Seropositivity;   HIV Infections;   HIV-1-infection Interventions:   Drug: Raltegravir;   Drug: Lamivudine Sponsors:   David Garcia Cinca;   Fundació Clínic per a la Recerca Biomèdica Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials